Hepatology Highlights
Jean‐François Dufour – 23 April 2014
Corrections
23 April 2014
Hepatology Highlights
Jean‐François Dufour – 23 April 2014
Cyclic guanosine monophosphate/adenosine monophosphate synthase (cGAS), innate immune responses, and viral hepatitis
Eloi R. Verrier, Michaela U. Gack, Thomas F. Baumert – 22 April 2014
The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?
Mario U. Mondelli – 22 April 2014
Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders
- Read more about Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders
Mohamed A. Chinnaratha, Uthayanan Chelvaratnam, Katherine A. Stuart, Simone I. Strasser, Geoffrey W. McCaughan, Paul Gow, Leon A. Adams, Alan J. Wigg, on behalf of the Australia and New Zealand Liver Transplant Clinical Study Group – 21 April 2014 – An increased liver disease burden has been reported for Aboriginal and Torres Strait Islanders (ATSIs) in Australia; however, few proceed to liver transplantation (LT).
Reply
Neung Hwa Park, Seok Won Jung, Eun‐Soon Shin, Young‐Hwa Chung – 20 April 2014
Prognostic impact of telomere maintenance gene polymorphisms in hepatocellular carcinoma patients: Some issues need to be clarified
Fei Liu, Wen‐Tao Wang, Yong‐Gang Wei, Bo Li – 20 April 2014
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
Pierre Bedossa, the FLIP Pathology Consortium – 19 April 2014 – Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity.